Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting.
IF 29.5
1区 医学
Q1 HEMATOLOGY
引用次数: 0
Abstract
Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups, offering hope for improved patient outcomes. Ongoing studies, like KOMET-008, further explore the synergistic potential of menin inhibitors in combination regimens, shaping future AML management strategies.
治疗急性髓性白血病的 Menin 抑制剂：2023 年 ASH 年会的最新进展。
2023年ASH年会上重点介绍了治疗复发或难治性急性髓性白血病（AML）的menin抑制剂的最新进展。值得注意的是，revumenib显示出了良好的疗效，与地西他滨/西达嘧啶和venetoclax联用时达到了100%的ORR。这些发现强调了menin抑制剂在改变急性髓细胞性白血病治疗方面的潜力，尤其是在基因定义的亚组中，为改善患者预后带来了希望。KOMET-008等正在进行的研究将进一步探索menin抑制剂在联合治疗方案中的协同潜力，从而塑造未来的急性髓细胞性白血病治疗策略。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
48.10
自引率
2.10%
发文量
169
审稿时长
6-12 weeks
期刊介绍：
The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts.
Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
